Schering To Create Third R&D Facility Under N.J. Consolidation Program
Executive Summary
Schering-Plough will develop its Summit site into the company's third major New Jersey R&D facility under a consolidation plan for its home state locations
You may also be interested in...
The 10% Solution: Roche Cuts U.S. Sales Force, Schering Reduces Payroll
Roche is cutting its U.S. sales force by 10% before the end of the year
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials